SARCLISA: payments to doctors
Payments that named SARCLISA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $8.9M
- Providers
- 9,623
- Transactions
- 39,466
- Average per transaction
- $227
The per-transaction average — $227 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 9,623 providers the average total is $930, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $8,412,237 | 94.0% |
| Sanofi-aventis U.S. LLC | $466,038 | 5.2% |
| Sanofi US Services Inc. | $71,301 | 0.8% |
| Sanofi Pasteur Inc. | $61 | 0.0% |